Menu

Light’s Dark Side

Exposure to dim light at night speeds the growth of human breast cancer tumors implanted into rats and makes the cancer resistant to the drug tamoxifen.

Jul 25, 2014
Kate Yandell

FLICKR, JO NAYLORExposure to even a low level of light at night makes implanted human breast cancer tumors grow faster in rats and makes the cancer cells impervious to the drug tamoxifen, according to a study published today (July 25) in Cancer Research. The researchers attributed these effects to light’s suppression of melatonin production, and showed that administering melatonin in the rodents’ drinking water helped eliminate the negative effects of light exposure.

“The implication is that it may be possible to overcome the insensitivity of some tumors in cancer patients by giving supplemental melatonin,” Russel Reiter, a professor of cell biology at the University of Texas Health Science Center in San Antonio who was not involved in the study, wrote in an e-mail to The Scientist. He added that the idea should be tested in clinical trials “as soon as possible.”

“I think it’s pretty much consistent with our growing knowledge that lifestyle is an enormous influence on breast cancer,” said Pamela Munster, a professor of medicine at the University of California, San Francisco, who also was not involved with the study.

Exposure to light at night in humans has been linked epidemiologically to many cancers, including breast cancer. The brain usually secretes the hormone melatonin at night, but light exposure dampens melatonin production. Melatonin has been previously shown to inhibit pathways leading to cancer growth and progression. Many of these pathways are also involved in making breast cancer tumors resistant to tamoxifen, a breast cancer drug that works by binding to estrogen receptors on tumor cells, blocking the hormone from doing so.

Tulane University School of Medicine’s Steven Hill worked with his colleagues to implant human breast cancer tumors into rats. They put the control rats on a normal schedule of 12 hours of light followed by 12 hours of complete darkness. A second group was on a schedule of 12 hours of light followed by 12 hours of very dim light—the amount you might see if you were in a completely dark room save for a crack of light peeking from underneath a door. This quantity of light suppresses rats’ melatonin production without more generally interrupting the timing of their circadian behaviors, such as drinking and eating.

The tumors of rats that were exposed to dim light at night grew 2.5 times faster than those of the controls. When the researchers attempted to shrink light-exposed rats’ tumors with tamoxifen, the tumors continued to grow at the same rate, whereas the tumors in the control rats notably shrunk.

The researchers next sacrificed the rats and analyzed their tumors. In the tumors of the light-exposed rats, several signaling molecules showed changes in phosphorylation associated with cancer progression and tamoxifen resistance. The tumors of light-exposed rats also showed alterations in metabolism typical of cancer, switching from using aerobic processes to using anaerobic glycolysis to produce energy. The tumors of control rats showed more subtle cancer-related changes.

When the researchers gave the rats melatonin at night, the controls and the rats exposed to dim light showed similar tumor growth and responsiveness to tamoxifen. This suggested that altered melatonin production was indeed responsible for increased cancer growth in the animals exposed to light at night.

Hill said he is not yet sure how melatonin dampens tamoxifen resistance. And he is unsure whether the hormone is affecting multiple pathways at once or affecting one signaling molecule that leads to multiple downstream changes.

He and his colleagues are now testing the effects of dim light and melatonin in prostate cancer. “We’ve seen some of the same phenomena [as in breast cancer],” he said.

Hill’s team will also attempt to validate their findings in human patients. Melatonin has already been tested clinically as a way to enhance tamoxifen’s efficacy at slowing cancer progression with modest success. But Hill said he hopes that having patients take the drugs before bedtime, rather than during the day, could help.

“We are not advocating that people with breast cancer go out and buy melatonin supplements,” said Hill. But he is ready to advise cancer patients to let their own melatonin production reach its full potential by getting plenty of sleep in complete darkness. He said that it is not yet clear exactly how much light exposure is needed to disrupt melatonin in humans, but that it could be a very small amount, such as the glow from a computer screen or a street lamp.

“If in the clinical setting melatonin also enhances the sensitivity of otherwise resistant tumors to tamoxifen, it would be a major advance in cancer treatment,” said Reiter.

R.T. Dauchy et al., “Circadian and melatonin disruption by exposure to light at night drive intrinsic resistance to tamoxifen therapy in breast cancer,” Cancer Research, doi:10.1158/0008-5472.CAN-13-3156, 2014.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.